Placebo News and Research RSS Feed - Placebo News and Research

Research findings highlight power of expectations to drive brain activity in Parkinson's patients

Research findings highlight power of expectations to drive brain activity in Parkinson's patients

Learning-related brain activity in Parkinson's patients improves as much in response to a placebo treatment as to real medication, according to a new study by researchers at the University of Colorado Boulder and Columbia University. [More]
Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI). [More]
AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases. [More]
Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine. [More]
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014. [More]
Omega-3 benefits may be sustained in early psychosis

Omega-3 benefits may be sustained in early psychosis

The positive effects of omega-3 supplementation seen in patients at high risk of psychosis in a previous randomised, controlled trial may be sustained, the investigators reported at the International Early Psychosis Conference in Tokyo, Japan. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]
Common anti-malaria medicine could have significant impact on colorectal cancer

Common anti-malaria medicine could have significant impact on colorectal cancer

Medical experts say a common malaria drug could have a significant impact on colorectal cancer providing a cheap adjunct to current expensive chemotherapy. [More]
Nonlinear correlation between axitinib dose, dBP increase

Nonlinear correlation between axitinib dose, dBP increase

A pharmacokinetic–pharmacodynamic model shows that diastolic blood pressure rises with increasing doses of axitinib in patients with metastatic renal cell carcinoma, US researchers report, although this relationship is not linear. [More]
Early sodium supplementation improves weight gain in premature infants

Early sodium supplementation improves weight gain in premature infants

Early sodium supplementation for very premature infants can enhance weight gain according to a recent study by researchers at the University of Cincinnati Medical Center and Cincinnati Children's Hospital Medical Center. [More]
New oral medication shows promise in treating fibromyalgia

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial. [More]
Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium levels). The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014. [More]
Adding ezetimibe to statin therapy reduces cardiovascular events

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events. [More]
NIH study finds limited kidney benefit from more rigorous blood pressure treatment

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. [More]
No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show. [More]
Smart drug Modafinil can impair cognitive performance in healthy students

Smart drug Modafinil can impair cognitive performance in healthy students

It is claimed one in five students have taken the 'smart' drug Modafinil to boost their ability to study and improve their chances of exam success. [More]
Oxytocin hormone inhibits fear center in brain, shows study

Oxytocin hormone inhibits fear center in brain, shows study

Frightening experiences do not quickly fade from memory. A team of researchers under the guidance of the University of Bonn Hospital has now been able to demonstrate in a study that the bonding hormone oxytocin inhibits the fear center in the brain and allows fear stimuli to subside more easily. [More]
Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Rare mutations that shut down a single gene are linked to lower cholesterol levels and a 50 percent reduction in the risk of heart attack, according to new research from Washington University School of Medicine in St. Louis, the Broad Institute at Massachusetts Institute of Technology and Harvard, and other institutions. [More]
Vitamin B12, folic acid supplements may not reduce risk of memory and thinking problems

Vitamin B12, folic acid supplements may not reduce risk of memory and thinking problems

Taking vitamin B12 and folic acid supplements may not reduce the risk of memory and thinking problems after all, according to a new study published in the November 12, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. The study is one of the largest to date to test long-term use of supplements and thinking and memory skills. [More]